KBC Group NV Buys 796 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

KBC Group NV increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 85,362 shares of the medical research company’s stock after acquiring an additional 796 shares during the period. KBC Group NV’s holdings in Charles River Laboratories International were worth $15,758,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of CRL. Wellington Management Group LLP boosted its holdings in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after buying an additional 3,738,018 shares during the last quarter. State Street Corp raised its holdings in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after buying an additional 509,163 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Charles River Laboratories International by 6.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock worth $101,483,000 after acquiring an additional 32,311 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.3 %

Shares of Charles River Laboratories International stock opened at $163.61 on Wednesday. Charles River Laboratories International, Inc. has a 1 year low of $160.85 and a 1 year high of $275.00. The company has a market capitalization of $8.37 billion, a price-to-earnings ratio of 20.48, a P/E/G ratio of 5.94 and a beta of 1.38. The business has a fifty day simple moving average of $185.87 and a two-hundred day simple moving average of $196.49. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the prior year, the firm earned $2.72 EPS. The business’s revenue was down 1.6% on a year-over-year basis. Research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Analysts Set New Price Targets

CRL has been the topic of several recent research reports. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group cut their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 target price for the company. Finally, UBS Group reissued a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $204.38.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).